Rentosertib, an AI-generated small molecule targeting Traf2- and Nck-interacting kinase, was safe and improved FVC in ...

SAN FRANCISCO — The investigational oral agent nerandomilast was superior to placebo at slowing the decline in forced vital capacity (FVC) among patients with progressive pulmonary fibrosis (PF ...

The FVC curves for the nerandomilast groups separated from that for the placebo group shortly after randomization . Figure 2 Changes from Baseline to Week 52 in the Forced Vital Capacity (FVC).

SAN FRANCISCO — Two doses of 52-week nerandomilast, a phosphodiesterase 4B inhibitor, lowered FVC decline vs. placebo in patients with progressive pulmonary fibrosis, according to results ...

By comparison, in the first round of results, in patients who had received deupirfenidone for 26 weeks, the FVC decline came in at -21.5 mL. This result was also within the expected natural ...

Patients taking 18 mg of nerandomilast experienced an adjusted mean FVC decline of 114.7 mL compared with 183.5 mL in the placebo group, with an adjusted difference of 68.8 mL (95% CI, 30.3-107.4 ...

Mean change from baseline in the percentage of predicted forced vital capacity (FVC) over that period was 6.75 percentage points with prednisone and 6.11 percentage points with methotrexate, which ...